Free Trial

Bicara Therapeutics (BCAX) Competitors

Bicara Therapeutics logo
$10.84 -0.73 (-6.31%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$10.90 +0.06 (+0.60%)
As of 06/13/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BCAX vs. APLS, XENE, AMRX, MIRM, ARWR, NAMS, RXRX, KNSA, VCEL, and GMTX

Should you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.

Bicara Therapeutics vs. Its Competitors

Bicara Therapeutics (NASDAQ:BCAX) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation.

In the previous week, Apellis Pharmaceuticals had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 11 mentions for Apellis Pharmaceuticals and 10 mentions for Bicara Therapeutics. Apellis Pharmaceuticals' average media sentiment score of 1.34 beat Bicara Therapeutics' score of 0.74 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicara Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Apellis Pharmaceuticals
6 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bicara Therapeutics has higher earnings, but lower revenue than Apellis Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicara TherapeuticsN/AN/AN/AN/AN/A
Apellis Pharmaceuticals$775.84M3.05-$528.63M-$1.79-10.52

Bicara Therapeutics currently has a consensus price target of $31.86, suggesting a potential upside of 193.90%. Apellis Pharmaceuticals has a consensus price target of $40.05, suggesting a potential upside of 112.71%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Bicara Therapeutics is more favorable than Apellis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicara Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00
Apellis Pharmaceuticals
0 Sell rating(s)
9 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.62

Apellis Pharmaceuticals received 336 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 72.73% of users gave Bicara Therapeutics an outperform vote while only 66.29% of users gave Apellis Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Bicara TherapeuticsOutperform Votes
16
72.73%
Underperform Votes
6
27.27%
Apellis PharmaceuticalsOutperform Votes
352
66.29%
Underperform Votes
179
33.71%

96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 15.5% of Bicara Therapeutics shares are owned by company insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bicara Therapeutics has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -34.97%. Bicara Therapeutics' return on equity of 0.00% beat Apellis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Bicara TherapeuticsN/A N/A N/A
Apellis Pharmaceuticals -34.97%-103.11%-28.96%

Summary

Bicara Therapeutics beats Apellis Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCAX vs. The Competition

MetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$630.98M$6.88B$5.57B$8.50B
Dividend YieldN/A2.48%5.27%4.17%
P/E RatioN/A8.4626.7519.66
Price / SalesN/A261.91403.98152.07
Price / CashN/A65.8538.2534.64
Price / BookN/A6.526.964.59
Net IncomeN/A$143.26M$3.23B$248.23M
7 Day Performance-5.74%-0.21%-1.22%-1.07%
1 Month Performance-25.09%10.62%6.34%2.59%
1 Year PerformanceN/A3.63%33.05%13.50%

Bicara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCAX
Bicara Therapeutics
2.0544 of 5 stars
$10.84
-6.3%
$31.86
+193.9%
N/A$630.98MN/A0.0032Analyst Revision
Gap Up
APLS
Apellis Pharmaceuticals
4.7584 of 5 stars
$19.39
+0.6%
$40.05
+106.6%
-55.2%$2.44B$775.84M-9.55770Analyst Revision
Gap Up
XENE
Xenon Pharmaceuticals
3.6567 of 5 stars
$31.45
-0.6%
$54.82
+74.3%
-12.1%$2.41B$7.50M-11.15210Positive News
Options Volume
Analyst Revision
AMRX
Amneal Pharmaceuticals
3.5293 of 5 stars
$7.61
-0.1%
$11.60
+52.4%
+12.5%$2.39B$2.83B-11.197,600
MIRM
Mirum Pharmaceuticals
3.2189 of 5 stars
$47.05
+1.4%
$60.73
+29.1%
+91.5%$2.33B$379.25M-23.29140Analyst Revision
ARWR
Arrowhead Pharmaceuticals
3.7013 of 5 stars
$16.57
-1.4%
$43.71
+163.8%
-39.1%$2.29B$545.21M-3.21400Analyst Upgrade
Analyst Revision
NAMS
NewAmsterdam Pharma
2.9594 of 5 stars
$20.16
+0.1%
$42.86
+112.6%
+5.3%$2.26B$47.14M-10.724Analyst Forecast
Analyst Revision
Gap Up
RXRX
Recursion Pharmaceuticals
1.9248 of 5 stars
$5.37
-2.2%
$7.60
+41.5%
-46.9%$2.23B$59.82M-3.51400Analyst Revision
Gap Down
High Trading Volume
KNSA
Kiniksa Pharmaceuticals
3.2302 of 5 stars
$30.33
+0.3%
$38.80
+27.9%
+50.8%$2.21B$481.17M-216.63220Analyst Upgrade
Insider Trade
VCEL
Vericel
2.4629 of 5 stars
$43.82
+1.2%
$61.14
+39.5%
+0.9%$2.21B$238.54M730.46300Positive News
Gap Down
GMTX
Gemini Therapeutics
N/A$50.02
+4.2%
N/A+37.2%$2.17BN/A-50.0230News Coverage

Related Companies and Tools


This page (NASDAQ:BCAX) was last updated on 6/15/2025 by MarketBeat.com Staff
From Our Partners